Sun Pharma ordered to halt Assam ophthalmic production after quality failures
AI Summary- Indian regulators ordered Sun Pharma to halt ophthalmic production, sales and distribution at its Assam facility.
- 332 batches of ophthalmic suspension products were covered by regulators’ information request after the recall.
- Sun Pharma submitted a compliance report, while regulators review the response to the Aug. 20 order.